Le Lézard
Classified in: Health
Subjects: NPT, SVY, MIN

Healthy Hearts Benefit from Daily Cranberry Consumption


New Research Reveals Cranberry Intake Improves Cardiovascular Health

CARVER, Mass., March 22, 2022 /PRNewswire/ -- A new clinical trial in Food & Function found daily consumption of cranberries for one month improved cardiovascular function in healthy men. The new study, Daily consumption of cranberry improves endothelial function in healthy adults: a double blind randomized controlled trial, included 45 healthy men who consumed whole cranberry powder equivalent to 1 cup of cranberries per day (9 g powder) or a placebo for one month. Those consuming cranberry had a significant improvement in flow-mediated dilation (FMD), which signals improvement of heart and blood vessel function. FMD is considered a sensitive biomarker of cardiovascular disease risk and measures how blood vessels widen when blood flow increases.

"The increases in polyphenols and metabolites in the bloodstream and the related improvements in flow-mediated dilation after cranberry consumption emphasize the important role cranberries may play in cardiovascular disease prevention," said Dr. Ana Rodriguez-Mateos, Senior Lecturer in Nutrition at the Department of Nutritional Sciences at King's College London. "The fact that these improvements in cardiovascular health were seen with an amount of cranberries that can be reasonably consumed daily makes cranberry an important fruit in the prevention of cardiovascular disease for the general public."

Low consumption of fruits and vegetables is one of the top modifiable risk factors associated with a higher incidence of cardiovascular disease worldwide. Growing evidence continues to link the polyphenols from berries with heart health benefits. Cranberries are rich in unique proanthocyanidins that have distinct properties compared to polyphenols found in other fruits. This study explored whole cranberry freeze-dried powder, equivalent to 100g or 1 cup of fresh cranberries, and its impact on cardiovascular health. The results demonstrated that consumption of cranberries as part of a healthy diet can help reduce the risk of cardiovascular disease by improving blood vessel function.

An initial pilot study was completed with five healthy young men to confirm the biological activity of the whole cranberry freeze-dried powder. The pilot concluded that cranberry consumption increased FMD and confirmed dosing. The main study was a gold standard study design examining 45 healthy men each consuming two packets of whole cranberry freeze-dried powder equivalent to 100g or 1 cup of fresh cranberries, or a placebo, daily for one month. The study found significant improvements in FMD two hours after first consumption and after one month of daily consumption showing both immediate and chronic benefit. In addition, metabolites were also identified and predicted the positive effects seen in FMD. These results conclude that cranberries can play an important role in supporting cardiovascular health and good blood vessel function.

"Our findings provide solid evidence that cranberries can significantly affect vascular health even in people with low cardiovascular risk," said Dr. Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey. "This study further indicates that specific metabolites present in blood after cranberry consumption are related to the beneficial effects."   

To read the study in its entirety, the Food & Function article can be accessed here: Daily consumption of cranberry improves endothelial function in healthy adults: a double blind randomized controlled trial.

The study was supported by the Cranberry Institute, the Research Committee of the Medical Faculty of Heinrich-Heine University Dusseldorf and the Susanne Bunnenberg Heart Foundation grant to Dusseldorf Heart Centre. For more information about the Cranberry Institute, along with the health benefits of cranberries and current scientific research, visit: www.CranberryInstitute.org.

About the Cranberry Institute
The Cranberry Institute is a not-for-profit organization founded in 1951 to further the success of cranberry growers and the industry in the Americas through health, agricultural and environmental stewardship research as well as cranberry promotion and education. The Cranberry Institute is funded voluntarily by Supporting Members that handle, process, and sell cranberries. Supporting Members are represented in national and international regulatory matters and research efforts are done on their behalf. 

Contact:
Emily Goldthwait
Pollock Communications
[email protected]
212-941-1414

SOURCE The Cranberry Institute


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: